Hand Infections Medication
- Author: Jordan Scaff, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD more...
The goals of pharmacotherapy are to eradicate the infection and to prevent complications. With the rise of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of hand infections, coverage with appropriate antibiotics is important.[6, 7] In this era, cephalexin alone is inappropriate coverage for hand infections, and coverage for all infections should include MRSA coverage.
Therapy must cover all likely pathogens in the context of the clinical setting.
First-generation cephalosporin that inhibits bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Primarily active against skin flora. Typically used for skin structure coverage and as prophylaxis in minor procedures. DOC for immunocompromised patients with paronychia.
Lincosamide useful as treatment against serious skin and soft tissue infections caused by most staphylococcal strains. Also effective against aerobic and anaerobic streptococci, except enterococci. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at bacterial ribosome where it preferentially binds to 50S ribosomal subunit, causing bacterial growth inhibition. DOC for paronychia in children and those who wash dishes.
Combination antimicrobial agent that uses a beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. DOC for infectious tenosynovitis and deep fascial space infections.
First-generation semisynthetic cephalosporin, which, by binding to 1 or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin-structure coverage. An alternate DOC for infectious tenosynovitis and deep fascial space infections.
Potent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or whose conditions have not responded to penicillins and cephalosporins or for those who have infections with resistant staphylococci. For abdominal penetrating injuries, combine with agent active against enteric flora and/or anaerobes. DOC (in conjunction with gentamicin) for infectious tenosynovitis and deep fascial space infections in patients who are allergic to penicillin. To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use CrCl to adjust dose in patients with renal impairment.
Aminoglycoside antibiotic used for gram-negative bacterial coverage. Used commonly in combination with both an agent against gram-positive organisms and an agent that covers anaerobes. DOC (in conjunction with vancomycin) for infectious tenosynovitis and deep fascial space infections in patients who are allergic to penicillin. Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution.
These agents are used to induce and boost active immunity.
Used to induce active immunity against tetanus in selected patients. Immunizing agents of choice for most adults and children >7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life.
Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product.
In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is mid thigh laterally.
These agents are used in the treatment of chronic paronychia. They have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.
An adrenocorticosteroid derivative suitable for application to skin or external mucous membranes. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
These agents are used in the treatment of chronic paronychia.
Broad-spectrum antifungal agent that inhibits yeast growth by altering cell membrane permeability, causing death of fungal cells. Reevaluate diagnosis if no clinical improvement after 4 wk.
Kanavel AB. Infections of the Hand. 1939. 17-410.
Ong YS, Levin LS. Hand infections. Plast Reconstr Surg. 2009 Oct. 124(4):225e-233e. [Medline].
Pintor E, Montilla P, Catalán P, Burillo A, Gargantilla P, Herreros B. Recurrent infection in the left thumb. Infection. 2013 May 7. [Medline].
Kapellen TM, Galler A, Kiess W. Higher frequency of paronychia (nail bed infections) in pediatric and adolescent patients with type 1 diabetes mellitus than in non-diabetic peers. J Pediatr Endocrinol Metab. 2003 Jun. 16(5):751-8. [Medline].
Rockwell PG. Acute and chronic paronychia. Am Fam Physician. 2001 Mar 15. 63(6):1113-6. [Medline].
Bach HG, Steffin B, Chhadia AM, Kovachevich R, Gonzalez MH. Community-associated methicillin-resistant Staphylococcus aureus hand infections in an urban setting. J Hand Surg [Am]. 2007 Mar. 32(3):380-3. [Medline].
Wilson PC, Rinker B. The incidence of methicillin-resistant staphylococcus aureus in community-acquired hand infections. Ann Plast Surg. 2009 May. 62(5):513-6. [Medline].
[Guideline] Hand hygiene recommendations. In: Betsy Lehman Center for Patient Safety and Medical Error Reduction, JSI Research and Training Institute, Inc. Prevention and control of healthcare-associated infections in Massachusetts. Part 1: final recommendations of the Expert Panel. Boston (MA): Massachusetts Department of Public Health; 2008 Jan 31. [Full Text].
Ergun A, Toprak R, Sisman FN. Impact of a Healthy Nails Program on Nail-Biting in Turkish Schoolchildren: A Controlled Pretest-Posttest Study. J Sch Nurs. 2013 Mar 14. [Medline].
Antosia RE, Lyn E. Hand. Rosen, ed. Emergency Medicine Concepts and Clinical Practice. 5th ed. 2002. 493-535.
Butler, KH. Incision and drainage. Roberts JR, Hedges JR, eds. Clinical Procedures in Emergency Medicine. 4th ed. 2004. 739-744.
Daniel CR 3rd, Daniel MP, Daniel J, Sullivan S, Bell FE. Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen. Cutis. 2004 Jan. 73(1):81-5. [Medline].
Gill MJ, Arlette J, Buchan K. Herpes simplex virus infection of the hand. A profile of 79 cases. Am J Med. 1988 Jan. 84(1):89-93. [Medline].
Goldstein EJ, Barones MF, Miller TA. Eikenella corrodens in hand infections. J Hand Surg [Am]. 1983 Sep. 8(5 Pt 1):563-7. [Medline].
Hausman MR, Lisser SP. Hand infections. Orthop Clin North Am. 1992 Jan. 23(1):171-85. [Medline].
Siegel DB, Gelberman RH. Infections of the hand. Orthop Clin North Am. 1988 Oct. 19(4):779-89. [Medline].
Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999 Jan 14. 340(2):85-92. [Medline].
Wolanyk DE. 17. Infections. Hart RG, Uehara DT, Wagner MJ, eds. Emergency and Primary Care of the Hand. Irving,Tx: The American College of Emergency Physicians; 2001. 219-246.